Metastatic Melanoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Active, not recruiting
  • Metastatic Melanoma
  • Skin Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
C
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Recruiting
  • Melanoma
  • +3 more
  • Phoenix, Arizona
  • +19 more
2022-04-06
Apr 6, 2022
C
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Recruiting
  • Melanoma
  • +3 more
  • Phoenix, Arizona
  • +24 more
2022-04-06
Apr 6, 2022
M
Pembrolizumab + Infliximab for Metastatic Melanoma
Recruiting
  • Metastatic Melanoma
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
2022-04-06
Apr 6, 2022
N
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Not yet recruiting
  • Metastatic Melanoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
N
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Active, not recruiting
  • Metastatic Melanoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
M
Radiotherapy & Combi in Metastatic Melanoma - 2020
Completed
  • Metastatic Melanoma
  • Palliative radiotherapy
  • Dabrafenib and trametinib (combination)
  • Darlinghurst, New South Wales, Australia
  • +2 more
2022-04-06
Apr 6, 2022
N
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +12 more
  • Tucson, Arizona
  • +44 more
2022-04-04
Apr 4, 2022
N
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Suspended
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +20 more
  • Ipilimumab
  • +3 more
  • Tampa, Florida
  • +7 more
2022-04-05
Apr 5, 2022
N
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Active, not recruiting
  • Metastatic Melanoma
  • +22 more
  • Ipilimumab
  • +3 more
  • Birmingham, Alabama
  • +24 more
2022-04-05
Apr 5, 2022
N
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +20 more
  • Pembrolizumab
  • Ziv-Aflibercept
  • Tampa, Florida
  • +8 more
2022-04-05
Apr 5, 2022
N
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Active, not recruiting
  • Metastatic Melanoma
  • +7 more
  • Dabrafenib Mesylate
  • +4 more
  • Birmingham, Alabama
  • +848 more
2022-04-05
Apr 5, 2022
N
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Recruiting
  • Advanced Differentiated Thyroid Gland Carcinoma
  • +102 more
  • Cabozantinib S-malate
  • Nivolumab
  • Chicago, Illinois
  • +2 more
2022-04-05
Apr 5, 2022
H
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Recruiting
  • Solid Tumors
  • +3 more
  • San Diego, California
  • +20 more
2022-04-04
Apr 4, 2022
D
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
Not yet recruiting
  • Malignant Melanoma
  • +4 more
  • (no location specified)
2022-03-31
Mar 31, 2022
N
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
Active, not recruiting
  • Malignant Solid Neoplasm
  • +7 more
  • Phoenix, Arizona
  • +48 more
2022-03-31
Mar 31, 2022
A
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Recruiting
  • Metastatic Melanoma
  • Hypofractionated Radiation Therapy (HFRT)
  • +2 more
  • Lancaster, Pennsylvania
  • +1 more
2022-03-30
Mar 30, 2022
I
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
Recruiting
  • Metastatic Melanoma
  • Miami, Florida
  • +4 more
2022-03-29
Mar 29, 2022
N
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Active, not recruiting
Has Results
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +8 more
  • Dabrafenib Mesylate
  • +2 more
  • Los Angeles, California
  • +15 more
2022-03-25
Mar 25, 2022
I
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Recruiting
  • Metastatic Melanoma
  • +2 more
  • Lifileucel
  • +5 more
  • La Jolla, California
  • +44 more
2022-03-23
Mar 23, 2022
N
A Study of NX-1607 in Adults With Advanced Malignancies
Recruiting
  • Ovarian Cancer, Epithelial
  • +13 more
  • Sutton, Surrey, United Kingdom
  • +3 more
2022-03-22
Mar 22, 2022
P
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Recruiting
  • Cancer Metastatic to the Liver
  • +9 more
  • PV-10 (10% rose bengal disodium)
  • San Diego, California
  • +4 more
2022-03-22
Mar 22, 2022
M
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain - 2022
Completed
  • Metastatic Malignant Neoplasm in the Brain
  • +4 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-21
Mar 21, 2022
M
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
Active, not recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +3 more
  • Quality-of-Life Assessment
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-08
Mar 8, 2022
F
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Active, not recruiting
  • Metastatic Melanoma
  • Boston, Massachusetts
  • +1 more
2022-03-22
Mar 22, 2022